FDA Brief

Warning letters Drugs

FDA warning letter to

EzriCare LLC

High riskIssued Feb 13, 2024Posted Feb 27, 2024Division of Pharmaceutical Quality Operations I

EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

What happened

FDA inspected EzriCare LLC in Lakewood, New Jersey, from March 8 to March 21, 2023, after an inspection at its contract manufacturer Global Pharma Healthcare found violative CGMP conditions. FDA testing of intact, unopened EzriCare Artificial Tears found 14 batches were non-sterile, with Pseudomonas aeruginosa isolates matching more than 85 clinical isolates in an outbreak that affected more than 80 patients and led to 4 deaths and at least 14 cases of vision loss; two samples also had visible foreign particles. FDA also found EzriCare, as a distributor, lacked adequate supplier qualification and complaint-handling procedures.

What FDA found

  1. EzriCare received and distributed EzriCare Artificial Tears that were adulterated because the contract manufacturer's CGMP violations made the eye drops non-sterile and contaminated.

    FD&C Act sections 501(a)(2)(B), 501(a)(2)(A), 301(a), and 301(c); 21 CFR Parts 210 and 211
  2. The company did not have adequate supplier qualification procedures to ensure Artificial Tears from Global Pharma Healthcare were made under CGMP before U.S. distribution.

    21 CFR Parts 210 and 211
  3. EzriCare could not provide written agreements or procedures showing it required its contract manufacturers to meet CGMP or make suitable release decisions.

    21 CFR Parts 210 and 211
  4. The company lacked written procedures for handling all written and oral product complaints and did not document or investigate complaints it received.

    21 CFR Parts 210 and 211
  5. EZRICARE Artificial Tears was misbranded because it was not sterile, and ophthalmic preparations are expected to be sterile.

    FD&C Act section 502(j); 21 CFR 200.50
  6. The eye drops were prepared, packed, or held under insanitary conditions that could contaminate them with filth or make them injurious to health.

    FD&C Act section 501(a)(2)(A)

What FDA wants

FDA asks EzriCare to provide a detailed plan to ensure it does not receive or deliver adulterated drugs, including full evaluation of its supplier and contract manufacturer qualification program and complaint handling, and to respond in writing within 15 working days.

Who should pay attention

  • distributors and private-label brands of ophthalmic drugs
  • companies relying on foreign contract manufacturers
  • quality teams managing supplier qualification and complaints

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk